Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
MultiMetaVerse Plans to Acquire Equity Stake in Taomee June 2, 2023
Janssen to Move forward with Clinical Development of LAVA Therapeutics’s Lead Gamma-Delta T-Cell Engager Bispecific Antibody June 2, 2023
Autolus Therapeutics to Present Positive Results from its Phase 2 FELIX study in adult r/r B-ALL at ASCO June 2, 2023
Connect Biopharma Higher on Positive Phase 2 Icanbelimod Trial Data June 2, 2023
Monopar Reports Positive Camsirubicin Phase 1b Trial Update June 1, 2023
Next
Prev

(Nasdaq:IMMX) ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. FDA Approved Drug Trabectedin

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
  • May 20, 2022 at 8:05 AM

(Nasdaq:IMMX) ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

  • One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)
  • In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs
  • IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030

RelatedNews

Page 1 of 6
12...6

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.